Entering text into the input field will update the search result below

European advisory group backs Oasmia's Apealea in ovarian cancer; shares up 28% premarket

Sep. 21, 2018 8:10 AM ETOasmia Pharmaceutical AB (publ) (OASM) StockBy: Douglas W. House, SA News Editor
  • Thinly traded micro cap Oasmia Pharmaceutical AB (OTC:OASM) is up 28% premarket on average volume on the heels of a positive opinion from the European Medicines Agency's advisory group CHMP backing approval for Apealea (paclitaxel micellar), combined with carboplatin, for the treatment of adult patients with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.
  • A final decision from the European Commission usually takes ~60 days.

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
OASM--
Oasmia Pharmaceutical AB (publ)